© 2023 PCMA. All Rights Reserved.
Don’t let the smoke and mirrors fool you:
.High drug costs start and end with big drug companies..
Congress needs to strengthen competition in the market and end big drug companies’ egregious abuse of the patent system that blocks affordable alternatives – such as generics and biosimilars – from entering the prescription drug market.
Clearing the Smoke
Pharmacy benefit companies save employers, labor union plans, and patients a whopping $124 billion per year on prescription drug costs.
American patients, employers, and unions will be left with fewer choices, less access, and higher costs if Big Pharma gets their way and pharmacy benefits are restricted.
Big drug companies choose to set out of reach prices for most Americans – then add insult to injury by blocking competition in the prescription drug market to maximize own their profit and drive drug costs higher at the expense of patients.
The median monthly price for newly approved drugs nearly tripled from $2,624 in 2011 to $7,034 in 2022. Increasing launch prices is just one tactic used to avoid attention on annual and repeated price hikes of existing drugs.
Legislation that supports competition, such as the “Affordable Prescriptions for Patients Act,” encourages greater competition to lower prescription drug costs for patients by targeting two common anti-competitive practices, patent thicketing and product hopping, which are utilized by big drug companies to block more affordable generics and biosimilars from entering the market.
See through big drug companies’ smoke and mirrors.
America’s more than 70 pharmacy benefit companies are working to lower prescription drug prices by increasing competition and ending big drug companies’ patent abuse that threatens pharmacy benefits.